Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


16 Items
Title  Creator  Group name  Publishing year 
Prognostic impact of the number and total tumor burden of secondary cerebral lesions in patients with resected brain metastases of non-small cell lung cancers Sauvageot et al. EquipeMY 2024-07-01
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases Bottosso et al. EquipeCTCS 2023-03
Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real-world data from a multicentric European cohort Ratosa et al. EquipeCTCS 2022-06-06
Detection of Circulating Tumor Cells in Cerebrospinal Fluid of Patients with Suspected Breast Cancer Leptomeningeal Metastases: A Prospective Study Darlix et al. EquipeCTCS 2022-10-06
Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer Darlix et al. EquipeCTCS 2021-10-15
Aspects cliniques : Cancers HER2 et atteinte du système nerveux central, que faire en 2021 ?: Central nervous system metastases from HER2 positive breast cancers: what to do in 2021? Bachelot et al. EquipeCTCS 2021-12
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort Pasquier et al. EquipeCTCS Jan 2020
The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases Darlix et al. EquipeCTCS Jan 30, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort Darlix et al. EquipeCTCS Dec 2019
High Levels of Cartilage Oligomeric Matrix Protein in the Serum of Breast Cancer Patients Can Serve as an Independent Prognostic Marker Papadakos et al. EquipeCTCS 2019
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer Darlix et al. EquipeCTCS Jun 2018
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience Griguolo et al. EquipeAP Feb 2018
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology Griguolo et al. EquipeCTCS Nov 2018
Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases? Darlix et al. EquipeCTCS 11 15, 2016
Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients Darlix et al. EquipeCTCS 07 07, 2016
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases Jacot et al. EquipeELC 06 2016
16 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés